219 related articles for article (PubMed ID: 23357204)
21. Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers.
Vilas D; Ispierto L; Álvarez R; Pont-Sunyer C; Martí MJ; Valldeoriola F; Compta Y; de Fabregues O; Hernández-Vara J; Puente V; Calopa M; Jaumà S; Campdelacreu J; Aguilar M; Quílez P; Casquero P; Lomeña F; Ríos J; Tolosa E
Parkinsonism Relat Disord; 2015 Oct; 21(10):1170-6. PubMed ID: 26306001
[TBL] [Abstract][Full Text] [Related]
22. Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease.
Ben Sassi S; Nabli F; Hentati E; Nahdi H; Trabelsi M; Ben Ayed H; Amouri R; Duda JE; Farrer MJ; Hentati F
Parkinsonism Relat Disord; 2012 Mar; 18(3):243-6. PubMed ID: 22056842
[TBL] [Abstract][Full Text] [Related]
23. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease.
White LR; Toft M; Kvam SN; Farrer MJ; Aasly JO
J Neurosci Res; 2007 May; 85(6):1288-94. PubMed ID: 17385669
[TBL] [Abstract][Full Text] [Related]
24. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.
Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL
J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023
[TBL] [Abstract][Full Text] [Related]
25. Exhaustion of mitochondrial and autophagic reserve may contribute to the development of LRRK2
Juárez-Flores DL; González-Casacuberta I; Ezquerra M; Bañó M; Carmona-Pontaque F; Catalán-García M; Guitart-Mampel M; Rivero JJ; Tobias E; Milisenda JC; Tolosa E; Marti MJ; Fernández-Santiago R; Cardellach F; Morén C; Garrabou G
J Transl Med; 2018 Jun; 16(1):160. PubMed ID: 29884186
[TBL] [Abstract][Full Text] [Related]
26. Altered reward-related neural responses in non-manifesting carriers of the Parkinson disease related LRRK2 mutation.
Thaler A; Gonen T; Mirelman A; Helmich RC; Gurevich T; Orr-Urtreger A; Bloem BR; Giladi N; Hendler T;
Brain Imaging Behav; 2019 Aug; 13(4):1009-1020. PubMed ID: 29971685
[TBL] [Abstract][Full Text] [Related]
27. The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: clinical and demographic characteristics.
Gatto EM; Parisi V; Converso DP; Poderoso JJ; Carreras MC; Martí-Massó JF; Paisán-Ruiz C
Neurosci Lett; 2013 Mar; 537():1-5. PubMed ID: 23340200
[TBL] [Abstract][Full Text] [Related]
28. G2019S LRRK2 mutation in familial and sporadic Parkinson's disease in Russia.
Pchelina SN; Yakimovskii AF; Ivanova ON; Emelianov AK; Zakharchuk AH; Schwarzman AL
Mov Disord; 2006 Dec; 21(12):2234-6. PubMed ID: 17044089
[TBL] [Abstract][Full Text] [Related]
29. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.
Floris G; Cannas A; Solla P; Murru MR; Tranquilli S; Corongiu D; Rolesu M; Cuccu S; Sardu C; Marrosu F; Marrosu MG
Parkinsonism Relat Disord; 2009 May; 15(4):277-80. PubMed ID: 18805725
[TBL] [Abstract][Full Text] [Related]
30. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.
Thaler A; Ash E; Gan-Or Z; Orr-Urtreger A; Giladi N
J Neural Transm (Vienna); 2009 Nov; 116(11):1473-82. PubMed ID: 19756366
[TBL] [Abstract][Full Text] [Related]
31. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
[TBL] [Abstract][Full Text] [Related]
32. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.
Somme JH; Molano Salazar A; Gonzalez A; Tijero B; Berganzo K; Lezcano E; Fernandez Martinez M; Zarranz JJ; Gómez-Esteban JC
Parkinsonism Relat Disord; 2015 May; 21(5):494-9. PubMed ID: 25840672
[TBL] [Abstract][Full Text] [Related]
33. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
[TBL] [Abstract][Full Text] [Related]
34. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
[TBL] [Abstract][Full Text] [Related]
35. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations.
Ruiz-Martínez J; Gorostidi A; Goyenechea E; Alzualde A; Poza JJ; Rodríguez F; Bergareche A; Moreno F; López de Munain A; Martí Massó JF
Mov Disord; 2011 Sep; 26(11):2026-31. PubMed ID: 21611983
[TBL] [Abstract][Full Text] [Related]
36. Genetic analysis of LRRK2 mutations in patients with Parkinson disease.
Deng H; Le W; Guo Y; Hunter CB; Xie W; Huang M; Jankovic J
J Neurol Sci; 2006 Dec; 251(1-2):102-6. PubMed ID: 17097110
[TBL] [Abstract][Full Text] [Related]
37. Identification of candidate genes for Parkinson's disease through blood transcriptome analysis in LRRK2-G2019S carriers, idiopathic cases, and controls.
Infante J; Prieto C; Sierra M; Sánchez-Juan P; González-Aramburu I; Sánchez-Quintana C; Berciano J; Combarros O; Sainz J
Neurobiol Aging; 2015 Feb; 36(2):1105-9. PubMed ID: 25475535
[TBL] [Abstract][Full Text] [Related]
38. DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers.
Artzi M; Even-Sapir E; Lerman Shacham H; Thaler A; Urterger AO; Bressman S; Marder K; Hendler T; Giladi N; Ben Bashat D; Mirelman A
PLoS One; 2017; 12(4):e0175424. PubMed ID: 28406934
[TBL] [Abstract][Full Text] [Related]
39. The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel.
Hassin-Baer S; Laitman Y; Azizi E; Molchadski I; Galore-Haskel G; Barak F; Cohen OS; Friedman E
J Neurol; 2009 Mar; 256(3):483-7. PubMed ID: 19412725
[TBL] [Abstract][Full Text] [Related]
40. [Clinical features of LRRK2-associated Parkinson's disease].
Pchelina SN; Ivanova ON; Emel'ianov AK; Iakimovskiĭ AF
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):56-62. PubMed ID: 22433811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
